Published • loading... • Updated
Innovent Announces Phase 3 CREDIT-5 Study Met Primary Endpoint, SINTBILO® (Tafolecimab Injection) as First-line Monotherapy Treatment for Hyperlipidemia Demonstrated Potent Lipid-lowering Efficacy
- Innovent announced that its Phase 3 CREDIT-5 study of SINTBILO® met its primary endpoint.
- After 12 weeks, SINTBILO® monotherapy reduced mean LDL-C levels by more than 60% at doses of 150 mg every two weeks or 450 mg every four weeks.
- The treatment lowered non-HDL-C, VLDL-C, ApoB, and Lp, while demonstrating favorable safety and no new safety signals.
- Innovent plans to submit a new indication application to China’s National Medical Products Administration.
Insights by Ground AI
17 Articles
17 Articles
Napa Valley Register+16 Reposted by 16 other sources
Innovent Announces Phase 3 CREDIT-5 Study Met Primary Endpoint, SINTBILO® (Tafolecimab Injection) as First-line Monotherapy Treatment for Hyperlipidemia Demonstrated Potent Lipid-lowering Efficacy
SINTBILO® (tafolecimab injection) monotherapy achieved significant reduction of LDL-C level, with > 60% mean LDL-C reduction after 12 weeks of treatment with 150 mg Q2W/450 mg Q4WSINTBILO® (tafolecimab injection) monotherapy significantly decreased non-HDL-C, vLDL-C, ApoB, and Lp(a) after 12-week treatment,…
Coverage Details
Total News Sources17
Leaning Left2Leaning Right1Center13Last UpdatedBias Distribution81% Center
Bias Distribution
- 81% of the sources are Center
81% Center
13%
C 81%
Factuality
To view factuality data please Upgrade to Premium
